No Data
Xiamen Kingdomway Group (002626.SZ): has obtained a USA invention patent certificate.
On December 16, Gelonghui reported that Xiamen Kingdomway Group (002626.SZ) announced that the company and its wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd., as well as its wholly-owned subsidiary Xiamen Kingdomway Biotechnology (Jiangsu) Co., Ltd., recently received an invention patent certificate issued by the USA Patent and Trademark Office. The invention is titled: ANTI-AGING DRUG COMBINATION AND USE THEREOF, patent number: US12,156,882B2. The effective period (protection period) is twenty years (calculated from the date of application). This invention.
Xiamen Kingdomway Group (SZSE:002626) Sheds CN¥378m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Xiamen Kingdomway Group (002626.SZ): The recently announced adjustment to the export tax rebate policy does not involve the company's products.
Gelonghui on November 20th | Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the announcement of the adjustment of export tax rebate policy recently issued by the Ministry of Finance and the State Administration of Taxation does not involve the company's products.
Xiamen Kingdomway Group (002626.SZ): Approval from the China Securities Regulatory Commission for the issuance of convertible csi enterprise bonds to unspecified objects.
Gelonghui, November 19 -- Xiamen Kingdomway Group (002626.SZ) announced that it recently received the "Approval on Xiamen Kingdomway Group Co., Ltd. to Issue Convertible Bonds to Unspecified Objects" from the China Securities Regulatory Commission (Document No. 1567 [2024]), approving the company's application to issue convertible bonds to unspecified objects. This approval is valid for 12 months from the date of approval.
Xiamen Kingdomway Group (002626.SZ): After the completion of the Coenzyme Q10 renovation and expansion project, the company's Coenzyme Q10 production capacity can reach about 900 tons.
Gelonghui November 13th | Xiamen Kingdomway Group (002626.SZ) stated on November 13, 2024, during a specific research visit, that the coenzyme Q10 renovation and expansion project is proceeding as planned, with smooth progress at present. After the renovation and expansion is completed, the company's coenzyme Q10 production capacity can reach around 900 tons.
xiamen kingdomway group (002626.SZ): the company has become the world's largest producer of coenzyme Q10.
Gelonghui November 13th | Xiamen Kingdomway Group (002626.SZ) stated on November 13, 2024, during a specific target survey, that as the company's synthetic biology production technology matures, the comprehensive manufacturing cost continues to decrease. The production cost advantage of Coenzyme Q10 becomes increasingly significant. With the advantages of high purity, high content, and high quality products, as well as the continuous accumulation of the company's brand influence and customer resources, the company has become the world's largest producer of Coenzyme Q10.